Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 14, 1997

View Archived Issues

New compounds for heparin reversal disclosed by University of Michigan

Merck & Co. discloses novel antifungal agents

Thomae reports agents for hypercholesterolemia

More oxazolidinone antimicrobial agents under study at P&U

Neurogen reports CRF ligands for stress-related disorders

Chiroscience reports new peptidyl compounds for treating degenerative diseases

Nitric oxide synthase inhibitors reported by Searle

Company Profile: NeoTherapeutics, Inc.

cGMP PDE inhibitors from Taisho

Kao discloses cell adhesion inhibitors

Thomas Jefferson University claims new apoptotic cysteine protease

Genetics Institute reports new bone morphogenic protein

Amgen discloses novel eck receptor ligands

New Canadian generic joint venture

Carrington Laboratories enters Middle East and African markets

HemoCleanse licenses bioartificial liver technology from Monsanto

Canadian launch for antiobesity drug

Ion exercises option to license sickle cell anemia Rx

Cell Genesys and Somatix to merge

Subcutaneous BDNF not effective in ALS

Avid licenses protease inhibitor from DuPont Merck

Approval for Neoprobe's first product

Gliatech licenses ADCON products in Japan

Annual review of activities at Collagen Corp.

FDA to review AmBisome NDA

Company Profile: Houghten Pharmaceuticals

Second IND submitted for new ADHD therapy

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 21, 2026
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...